Related Experiment Video
Updated: May 9, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
[MSB-43] Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension: Our Initial Experience
Selim Aydin1, Bahar Temur1, Yakup Tire2
1Department of Cardiovascular Surgery, Acıbadem University School of Medicine, İstanbul, Türkiye.
Objective:
This study aimed to share the early results of the pulmonary endarterectomy program recently implemented in our clinic in the treatment of chronic thromboembolic pulmonary hypertension.
Methods:
Eighteen patients (10 females, 8 males; mean age: 46 years) who underwent pulmonary endarterectomy between October 2022 and August 2024 were included in the retrospective study. Perioperative and follow-up data, including age, in-hospital mortality, and the length of intensive care unit and hospital stays after pulmonary endarterectomy, were evaluated.
Results:
The majority of the patients (n=16) were New York Heart Association class III or IV before surgery. According to the University of California, San Diego level classification, almost all patients had at least level 1 and 2 lesions in one or more pulmonary artery (n=17). Cardiopulmonary bypass time, cross-clamp time, and total circulatory arrest time were 174.8±16.6, 34.7±12.2, and 21,7±6.2 min, respectively. The in-hospital mortality rate was 5.5% (n=1), and the morbidity rate was 16.6% (n=3). Extracorporeal membrane oxygenation was performed on two patients (one venoarterial, one venovenous). Both patients were successfully weaned off ECMO. However, the patient who received venoarterial ECMO died due to multiorgan failure in the second postoperative month. After pulmonary endarterectomy, the durations of mechanical ventilation, intensive care stay, and hospital stay before discharge were 6.1±13.1, 17.8±14.7, and 20.01±13.9 days, respectively. The systolic and mean pulmonary artery pressure fell from 97.6±22.6 and 63.1±18.1 mmHg before surgery to 42.5±12.8 and 25.7±6.1 mmHg after surgery.
Conclusion:
Pulmonary endarterectomy is a highly effective treatment for chronic thromboembolic pulmonary hypertension, providing dramatic clinical improvement in the early term with acceptable mortality and morbidity rates.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pneumothorax-II
Clinical Manifestations:

